Table 1.
Characteristics of the study and control group. NACT= neoadjuvant chemotherapy
| Study group (n=104) | Control group (n=202) | |
|---|---|---|
| Age (in years) | Mean: 62.00 | Mean: 58.35 |
| Tumor stage | ||
| FIGO I | 10.7% (n=11 ) | 33.2% (n=67 ) |
| FIGO II | 2.9% (n=3 ) | 9.4% (n=19 ) |
| FIGO III | 53.4% (n=55 ) | 29.7% (n=60 ) |
| FIGO IV | 31.1% (n=32 ) | 17.8% (n=36 ) |
| Unknown | 1.9% (n=2 ) | 9.9% (n=20) |
| Histology | ||
| High-grade serous ovarian carcinoma | 85.7% (n=66 ) | 66.1% (n=72) |
| Mucinous ovarian carcinoma | 3.9% (n=3 ) | 14.7% (n=16) |
| Endometrioid ovarian carcinoma | 6.5% (n=5 ) | 12.8% (n=14) |
| Clear cell ovarian carcinoma | 3.9% (n=3 ) | 6.4% (n=7) |
| NACT performed | 57.3% (n=59 ) | 33.7% (n=68) |
| Colonoscopy Findings | ||
| Abnormality | 38.8% (n=40 ) | 0.0% (n=0 ) |
| Colorectal resection/shaving | ||
| Resection | 32.0% (n=33 ) | 15.3% (n=31 ) |
| Shaving | 3.9% (n=4 ) | 1.5% (n=3 ) |
| Inoperability | 21.4% (n=22 ) | 14.4% (n=29 ) |
| No infestation (appendectomy for muc. carcinoma if necessary) | 42.7% (n=44 ) | 68.8% (n=139 ) |
| Postoperative tumor residue | ||
| Macroscopic complete resection | 67.0% (n=69) | 79.2% (n=160 ) |
| No macroscopic complete resection | 34.0% (n=35) | 20.8% (n=42 ) |